Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 6/20 | 1.00 |
| ▸ | ADH5 | P11766 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.59 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | RPA1 | P27694 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247247 | 0.85 | XDH (0.72) | XDHADH5KDM4EMEN1ALOX12 | |
| SCHEMBL17834028 | 0.82 | XDH (0.70) | XDHADH5KDM4EMEN1ALOX12 | |
| Hydrochloric Acid SCHEMBL28324107 | 0.82 | XDH (0.68) | XDHKDM4EMEN1ALOX12KMT2A | |
| SCHEMBL2653775 | 0.80 | XDH (0.67) | XDHKDM4EMEN1ALOX12KMT2A | |
| SCHEMBL9984638 | 0.80 | ADH5 (0.95) | XDHADH5MEN1KMT2ARPA1 | |
| SCHEMBL2157222 | 0.79 | XDH (0.65) | XDHADH5KDM4EMEN1ALOX12 | |
| SCHEMBL4634221 | 0.78 | XDH (0.63) | XDHNPC1RAB9AALDH1A1 | |
| SCHEMBL18262990 | 0.76 | KDM4E (0.81) | XDHKDM4EMEN1ALOX12KMT2A | |
| SCHEMBL2645809 | 0.75 | ADH5 (0.75) | XDHADH5RPA1ATMTP53 | |
| SCHEMBL25216798 | 0.74 | XDH (0.59) | XDHADH5KDM4EMEN1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025034789-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK DEGRADERS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-02-13 | — | — | WO | disclosed |
| EP-3256461-B1 | UREA AND SULFONAMIDE DERIVATIVES AS HUMAN HELICASE DDX3 INHIBITORS USEFUL IN THE TREATMENT OF VIRAL DISEASES | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2023-09-13 | — | — | EP | disclosed |
| CN-114072000-A | Molecules having certain pesticidal effects and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3432881-B1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2021-11-24 | — | — | EP | disclosed |
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-05-11 | — | — | US | disclosed |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-03-09 | — | — | US | disclosed |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2020-05-07 | — | — | US | disclosed |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENRESE (IT) | 2019-04-04 | — | — | US | disclosed |
| EP-3432881-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | Azienda Ospedaliera Universitaria Senese (IT) | 2019-01-30 | — | — | EP | disclosed |
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2018-01-18 | — | — | US | disclosed |
| WO-2016128541-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2016-08-18 | — | — | WO | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20060258561-A1 | Novel NPH insulin preparations | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| CN-1787833-A | Pharmaceutical preparation comprising acid-stabilized insulin | NOVO NORDISK AS (DK) | 2006-06-14 | — | — | CN | disclosed |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | NOVO NORDISK A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| CN-1558762-A | Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer | ŵ��Ų�ڿ˹�˾ | 2004-12-29 | — | — | CN | disclosed |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | DDX3X, DDX21, DDB1 | XDH 1558/4885ADH5 3756/4885KDM4E 1563/4885 |
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | XDH 987/4885ADH5 3180/4885KDM4E 2372/4885 |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | XDH 987/4885ADH5 3180/4885KDM4E 2372/4885 |
| US-20060258561-A1 | Novel NPH insulin preparations | IAPP, HBB, INSR | XDH 3896/4885ADH5 4701/4885KDM4E 4791/4885 |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | IAPP, GPR119, INSR | XDH 3793/4885ADH5 4346/4885KDM4E 4773/4885 |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | IAPP, IRS1, GPR119 | XDH 4061/4885ADH5 4662/4885KDM4E 4783/4885 |
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | XDH 392/4885ADH5 343/4885KDM4E 4375/4885 |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | DDX3X, DDX39B, DDX1 | XDH 987/4885ADH5 3180/4885KDM4E 2372/4885 |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | DDX21, DDX3X, DDB1 | XDH 1622/4885ADH5 3751/4885KDM4E 1596/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | XDH 4464/4885ADH5 4777/4885KDM4E 4665/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | XDH 4136/4885ADH5 4319/4885KDM4E 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.